Abstracts tagged "complement"

Abstract Number: 1606 • ACR Convergence 2025
One Year Real-World Effectiveness with Avacopan in Granulomatosis with Polyangiitis and Microscopic Polyangiitis in a Large Healthcare System
Naomi Patel¹, Andrew King², Madison Negron³, Zachary Williams⁴, Ana Fernandes¹, Nora Shepherd², Colebrooke Johnson¹, Guy Katz¹, Belen Arevalo Molina¹, Elizabeth Ibiloye⁵, Sam Oh⁶, Zachary Wallace⁷ and Sebastian H Unizony⁸, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Harvard Extension School, Medford, MA, ⁴Massachusetts General Hospital, Nancy, KY, ⁵Amgen Inc, Thousand Oaks, CA, ⁶Amgen Inc, South San Francisco, CA, ⁷Massachusetts General Hospital, Newton, MA, ⁸Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Avacopan has been approved for adjunctive use in adults with severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in the US. Here…
Abstract Number: 0922 • ACR Convergence 2025
Phenotypic and Transcriptomic Divergence in C3 Glomerular Mouse Models: Insights into Immune and Sex Correlates
Juan Liang¹ and kaiyuan zi², ¹Gempharmatech, Nanjing, Jiangsu, China, ²Gempharmatech, Nanjing, Jiangsu, Jiangsu, China
Background/Purpose: Complement component C3 plays a central role in the alternative pathway (AP) and is implicated in the pathogenesis of C3 glomerulopathy (C3G), a rare…
Abstract Number: 0896 • ACR Convergence 2025
Does complement product C5a and its receptor C5a receptor 1 play a role in giant-cell arteritis?
marc Corbera-bellalta¹, Nuria Farran-Centelles², Nina Visocnik¹, Sergio Prieto-Gonzalez³, Jose hernandez-rodriguez⁴, javier Marco-hernandez⁵, Georgina Espigol-Frigolé¹ and Maria Cid⁶, ¹Hospital Clínic. University of Barcelona. IDIBAPS., Barcelona, Spain, ²Autoimmune diseases, Barcelona, Spain, ³Hospital Clinic, Barcelona, Catalonia, Spain, ⁴Hospital Clinic. University of Barcelona. IDIBAPS, Barcelona, Catalonia, Spain, ⁵Hospital Clinic.University of Barcelona. IDIBAPS, Barcelona, Catalonia, Spain, ⁶Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: Patients with giant-cell arteritis (GCA) are in an unmet need for reduction of GC exposure because of the high incidence of GC-related side effects…
Abstract Number: 0624 • ACR Convergence 2025
Polygenic risk of lupus is differentially associated with individual EHR-derived classification criteria
Noah Forrest¹, Sachleen Tuteja², Jennifer Pacheco³, Vesna Mitrovic³, Rosalind Ramsey-Goldman¹, Theresa Walunas³ and Matthew Dapas¹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Evanston, ³Northwestern University Feinberg School of Medicine, Chicago
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by diverse clinical presentation, posing significant challenges in diagnosis and management. Reflecting this clinical…
Abstract Number: 0856 • ACR Convergence 2025
Integrated Single-Cell and Spatial Transcriptomics Reveal Vascular and Immune Pathogenesis in APS Nephropathy
Shuyi Yu¹, Haoyu Pan¹, Jinyi Qian¹, Xiaohan Wei², Yuying Fan¹, Zhixia Yang¹, Shiyan Gu¹, Jianzhou Wu¹, Cenyi Wang¹, Tiancheng Zhou¹ and Hui Shi³, ¹Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ²Shanghai JiaoTong University, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To elucidate the molecular and cellular mechanisms underlying antiphospholipid antibody (aPL) nephropathy using integrated single-cell and spatial transcriptomic (SP) profiling of kidney tissues.Methods: Renal…
Abstract Number: 0821 • ACR Convergence 2025
Flipping The Switch – Classical Complement Activation closely linked to IFN-signalling in Stills Disease
Freya Huijsmans¹, Alejandra Bodelón de Frutos¹, Lyanne Sijbers¹, Susanne Benseler², Joost Swart³, Rae Yeung⁴, Sebastiaan Vastert⁵ and Jorg van Loosdregt¹, ¹Pediatric Rheumatology & Immunology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, Utrecht, Netherlands, ²Cumming School of Medicine, Department of Pediatrics, University of Calgary, Calgary, AB, Canada, ³Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Utrecht, Netherlands, ⁴The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁵University Medical Center Utrecht, Utrecht, Utrecht, Netherlands
Background/Purpose: Stills disease (SD) is an autoinflammatory syndrome characterized by severe innate immune dysregulation. The complement system, an essential component of innate immunity, can drive…
Abstract Number: 0807 • ACR Convergence 2025
Deciphering Synovitis in Systemic Sclerosis
Celina Geiss¹, Miranda Houtman¹, Camino Calvo Cebrian¹, Raphael Micheroli², Melpomeni Toitou¹, Yannis Djeffal³, Alexandra Khmelevskaya¹, Mojca Frank-Bertoncelj¹, Sam Edalat¹, Thomas Rauer⁴, Kristina Bürki⁵, Chantal Pauli⁶, Michael Bonelli⁷, Thomas Karonitsch⁸, Oliver Distler⁹, Caroline Ospelt¹ and Muriel Elhai¹⁰, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Zurich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³INSERM, IMRB, Université Paris Est Créteil, Paris, France, ⁴³Department of Traumatology, University Hospital Zurich, University of Zurich, Zurich, Zurich, Switzerland, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁶Institute for Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Zurich, Switzerland, ⁷Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Wien, Austria, ⁸Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹⁰University Hospital zurich, Zürich, Switzerland
Background/Purpose: Synovitis is a common manifestation of systemic sclerosis (SSc), driving disability and predicting disease progression and mortality. Current immunosuppressive strategies, largely extrapolated from rheumatoid…
Abstract Number: 0724 • ACR Convergence 2025
Risk of Drug Induced Liver Injury with Use of Avacopan in ANCA Vasculitis – Results from Real-World Data
Milad Heydari-Kamjani¹, Elleson Harper² and Haseeb Chaudhary³, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ³Case Western Reserve University, Westlake, OH
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic autoimmune vasculitis. Avacopan, a novel oral C5a receptor inhibitor, has emerged as an adjunct therapy…
Abstract Number: 1508 • ACR Convergence 2025
Dissecting the Role of T Cell Subsets and Complements in Lupus Pathogenesis in Systemic Lupus Erythematosus Patients with Obesity
Sheila Serin¹, Megan Schluentz¹, Chandana Keshavamurthy¹, Alexandra Reese¹, Sneha Centala¹, Bettina Boone¹, Samantha Ahrens², William Davis³, Robert Quinet¹, Jerald Zakem⁴, Samina Hayat⁵, Sarwat Umer⁶, Teresa leeth⁷, Daniyal Nadeem⁷ and Xin Zhang⁸, ¹Department of Rheumatology, Ochsner Health, New Orleans, LA, ²Multi-specialty Clinical Research, Ochsner Health, New Orleans, LA, ³Ochsner Health System, New Orleans, LA, ⁴Ochsner Health Systems, Metairie, LA, ⁵Louisiana state university Shreveport, Shreveport, LA, ⁶LSUHSC Shreveport, Shreveport, LA, ⁷Louisiana State University Health Science, Shreveport, LA, ⁸Ochsner Medical Center, New Orleans, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by systemic inflammation, autoantibody production, and multiorgan involvement. Although genetic, hormonal, and environmental factors…
Abstract Number: 2507 • ACR Convergence 2025
Reporting of infectious and hepatic adverse events with avacopan: insights from the World Health Organization pharmacovigilance database (VigiBase)
Camille Mettler¹, Laurent Chouchana² and Benjamin Terrier³, ¹Département de Médecine interne, Hôpital Bichat-Claude-Bernard, Paris, France, ²Département de Pharmacologie, Centre Régional de Pharmacovigilance, Hôpital Cochin, Paris, France, ³Cochin Hospital, Paris, France
Background/Purpose: Avacopan, an oral C5aR antagonist, is approved for the treatment of ANCA-associated vasculitis (AAV) as a steroid-sparing alternative. While clinical trials demonstrated a positive…
Abstract Number: 2434 • ACR Convergence 2025
Specificity of Cell-bound T Cell Biomarkers (TC4d, TIgG, TIgM) in Differentiating SLE from ANA-Associated Rheumatic Diseases
Vasileios Kyttaris¹, Sepehr Taghavi², Clayton Nagle³, Christine Schleif³, Brittany Partain⁴ and Tyler O'Malley⁵, ¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ²Exagen Inc, Escondido, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Exagen, Vista, CA
Background/Purpose: We previously validated T Cell-bound C4d (TC4d), T Cell-bound IgG (TIgG), and T Cell-bound IgM (TIgM) biomarkers, demonstrating high sensitivity and specificity for differentiating…
Abstract Number: 2433 • ACR Convergence 2025
The Clinical Utility of a Multianalyte Lupus Risk Score Incorporating Cell-bound Complement Activation Products: A Systematic Evaluation
Vasileios Kyttaris¹, Sepehr Taghavi², Clayton Nagle³, Christine Schleif³, Brittany Partain⁴ and Tyler O'Malley⁵, ¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ²Exagen Inc, Escondido, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Exagen, Vista, CA
Background/Purpose: Timely SLE diagnosis and treatment are critical to preventing irreversible organ damage and preserving quality of life. However, conventional biomarkers often underperform in patients…
Abstract Number: 2430 • ACR Convergence 2025
Disease Activity Independently Correlates with Cognitive Impairment in Systemic Lupus Erythematosus
Steven Beiser¹, Asma Qureshi¹, Komel Safdar², Zachary Orban¹, Mary Carns², Vanessa Manada De Lobos¹, Cecilia Stumpf³, Mohammad Daud Khan¹, Tyler Therron⁴, Anh Chung¹, Katherine Puev¹, Neil Pillai¹, Kathleen Aren⁵, John F Seagrist², Jing Song⁶, Jason Ross¹, Harris R Perlman², Yvonne Lee², Deborah Rachelle Winter⁷, Borna Bonakdarpour¹, Mariam Siddiqui⁸, Laura Arneson², Rosalind Ramsey-Goldman⁹, Lutfiyya muhammad⁹, Mary Mahieu⁹, Irene Blanco¹⁰, Eric Larson¹, Elena Grebenciucova¹ and Carla Marie Cuda², ¹Northwestern University, Chicago, ²Northwestern University, Chicago, IL, ³Northwestern University, Elmhurst, IL, ⁴Northwestern Feinberg School of Medicine, Chicago, IL, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶Northwestern University Feinberg School of Medicine, Worthington, MN, ⁷Northwestern University, Skokie, IL, ⁸Northwestern, Chicago, IL, ⁹Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Northwestern University, Oak Park, IL
Background/Purpose: Mechanisms driving cognitive impairment (CI) in systemic lupus erythematosus (SLE) remain poorly understood; conflicting results exist regarding the relationship between CI and disease activity.…
Abstract Number: 2381 • ACR Convergence 2025
Renal Tubular Complement C9 Deposition is Linked to Tubulointerstitial Fibrosis and Progression to Chronic Kidney Disease in Lupus Nephritis
Angela Lu¹, Daming Shao², Ying Jin¹, Luis Chiriboga³, Ming Wu⁴, James Pullman⁵, Anna Broder⁶ and Shudan Wang⁵, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Chicago, Chicago, IL, ³NYU Langone Medical Center, New York City, ⁴Northwell Health, New Hyde Park, ⁵Montefiore Medical Center, Bronx, NY, ⁶Hackensack University Medical Center, Hackensack, NJ
Background/Purpose: The complement system is known to play a central role in the pathogenesis of lupus nephritis (LN), one of the most severe manifestations of…
Abstract Number: 2033 • ACR Convergence 2025
Complement Fragments are Deposited in the Submandibular Glands in IgG4-Related Disease
Guy Katz¹, Judith Ferry¹, Grace McMahon¹, Isha Jha², Claire Galand³, Fei Liu⁴, Shelia Violette⁴, Jason Campagna⁴, Ana Fernandes¹, Cory Perugino⁵ and John Stone⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Q³² Bio Inc,, Waltham, MA, ⁴Q³² Bio Inc, Waltham, MA, ⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: Hypocomplementemia, defined as low serum C3 and/or C4 concentrations, is common in patients with IgG4-related disease (IgG4-RD). While this has historically been linked with…

1
2
3
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].